PHASE I CLINICAL TRIAL TARGETING CD20+NON-HODGKIN'S LYMPHOMA (NHL) AFTER AUTOLOGOUS STEM CELL TRANSPLANT WITH ANTI-CD3 x ANTI-CD20 BISPECIFIC ANTIBODY ARMED T CELLS

被引：1
|
作者：
Lum, L. G. [1 ]
Thakur, A. [1 ]
Ratanatharathorn, V [1 ]
Al-Kadhimi, Z. [1 ]
Paul, E. [1 ]
Skuba, C. [2 ]
Steel, P. [1 ]
Ayash, L. [1 ]
Abidi, M. [1 ]
Wedge, J. [1 ]
Uberti, J. P. [1 ]
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Michigan State Univ, Coll Vet Med, E Lansing, MI 48824 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2011年 / 17卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2010.12.027
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
23
引用
收藏
页码：S158 / S159
页数：2
相关论文
共 50 条
  • [41] Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody
    R M Sharkey
    H Karacay
    C-H Chang
    W J McBride
    I D Horak
    D M Goldenberg
    Leukemia, 2005, 19 : 1064 - 1069
  • [42] Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes
    Bannerji, Rajat
    Arnason, Jon E.
    Advani, Ranjana
    Brown, Jennifer R.
    Allan, John N.
    Ansell, Stephen M.
    Barnes, Jeffrey
    O'Brien, Susan M.
    Chavez, Julio C.
    Duell, Johannes
    Lowy, Israel
    Charnas, Robert
    Sternberg, David
    Ambati, Srikanth
    Adriaens, Lieve
    Ufkin, Melanie
    Yan, Xiaoyu
    Li, Jingjin
    Navarro, Mark
    Gasparini, Peter
    Jankovic, Vladimir
    Fiaschi, Nathalie
    Zhang, Wen
    Hamon, Sara
    Thurston, Gavin
    Topp, Max S.
    BLOOD, 2018, 132
  • [43] Pretarget radioimmunotherapy (RIT) with anti-CD20 fusion protein in patients with non-Hodgkin's lymphoma (NHL).
    Meredith, R
    Shen, S
    Breitz, H
    Fisher, D
    Goris, M
    Knox, S
    Hankins, J
    Vose, J
    Picozzi, V
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 116P - 117P
  • [44] Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
    Nirav N. Shah
    Bryon D. Johnson
    Dina Schneider
    Fenlu Zhu
    Aniko Szabo
    Carolyn A. Keever-Taylor
    Winfried Krueger
    Andrew A. Worden
    Michael J. Kadan
    Sharon Yim
    Ashley Cunningham
    Mehdi Hamadani
    Timothy S. Fenske
    Boro Dropulić
    Rimas Orentas
    Parameswaran Hari
    Nature Medicine, 2020, 26 : 1569 - 1575
  • [45] Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
    Shah, Nirav N.
    Johnson, Bryon D.
    Schneider, Dina
    Zhu, Fenlu
    Szabo, Aniko
    Keever-Taylor, Carolyn A.
    Krueger, Winfried
    Worden, Andrew A.
    Kadan, Michael J.
    Yim, Sharon
    Cunningham, Ashley
    Hamadani, Mehdi
    Fenske, Timothy S.
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    NATURE MEDICINE, 2020, 26 (10) : 1569 - +
  • [46] In vitro evaluation of pretargeting system with anti-CD20 mAb for targeting non-Hodgkin's lymphoma
    Kim, H.
    Lee, I.
    Shin, E.
    Lee, E.
    Chung, H.
    Shim, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S645 - S646
  • [47] Rituximab and Interleukin 2 (IL2) as treatment for CD20+non-Hodgkin's lymphoma (NHL) following autologous peripheral blood stem cell transplant (ASCT).
    Holmberg, LA
    Maloney, DG
    Bensinger, WI
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 566S - 566S
  • [48] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth
    Alinari, Lapo
    Earl, Christian Tyler
    Wilding, Emily
    Quinion, Carl
    Lustberg, Mark
    Benson, Don M., Jr.
    Jones, Jeffrey A.
    Byrd, John C.
    Wegener, William A.
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    BLOOD, 2010, 116 (21) : 1148 - 1149
  • [49] Application of monoclonal anti-CD20 antibody rituximab in the treatment. of non-Hodgkin's lymphoma
    Mihaljevic, Biljana
    Jankovic, Snezana
    Jakovic, Ljubomir
    Jovanovic, Maja Perunicic
    Andelic, Bosko
    Milosevic, Violeta
    Sretenovic, Aleksandra
    Virijevic, Marjana
    Petrovic, Milan
    VOJNOSANITETSKI PREGLED, 2008, 65 (03) : 229 - 233
  • [50] TRANSLATIONAL FINDINGS FOR REGN1979, A HUMAN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY: FROM PRECLINICAL TO FIRST-IN-HUMAN STUDY IN PATIENTS WITH CD20+B-CELL MALIGNANCIES.
    Zhu, M.
    Smith, E.
    Kirshner, J.
    Toroghi, M.
    Davis, J.
    Di-Cioccio, A.
    Retter, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S103 - S103
12345